Cytokinetics announces European Commission approval of MYQORZO (aficamten) for obstructive HCM

CYTOKINETICS INC

European Commission approved MYQORZO (aficamten) for symptomatic obstructive HCM in adults.
Approved dosage strengths: 5 mg, 10 mg, 15 mg, and 20 mg tablets.
MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity.
Indication covers NYHA class II-III obstructive hypertrophic cardiomyopathy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.